Related Experiment Videos
Antibodies against rHuEPO: native and recombinant
1Service d'Hématologie Biologique, Hôtel-Dieu, Paris, France. nicole.casadevall@htd.ap-hop-paris.fr
Summary
Sudden resistance to recombinant human erythropoietin (rHuEPO) in anemia patients was linked to neutralizing antibodies. Prompt detection and immunosuppressive treatment aided recovery in most cases.
Area of Science:
- Nephrology
- Immunology
- Hematology
Background:
- Recombinant human erythropoietin (rHuEPO) effectively treats anemia in chronic renal failure.
- Historically, neutralizing anti-erythropoietin antibodies were rare.
- A recent surge in cases of rHuEPO resistance and pure red cell aplasia has been observed.
Purpose of the Study:
- Investigate the cause of sudden resistance to rHuEPO in patients with anemia.
- Determine if neutralizing anti-erythropoietin antibodies are responsible for rHuEPO resistance.
- Evaluate the efficacy of immunosuppressive treatment for antibody-induced aplastic anemia.
Main Methods:
- Clinical assessment of patients presenting with rHuEPO resistance and pure red cell aplasia.
- Testing patient sera for neutralizing antibodies against erythropoietin.
- Inhibition assays of erythroid colony formation from normal bone marrow.
- Direct demonstration of anti-erythropoietin antibodies via immunoprecipitation.
Main Results:
- 21 patients referred with sudden resistance to rHuEPO and pure red cell aplasia.
- All patients exhibited strong neutralizing anti-erythropoietin antibodies.
- Immunosuppressive treatment led to antibody disappearance and recovery in 16 patients.
Conclusions:
- Neutralizing anti-erythropoietin antibodies are a significant cause of rHuEPO resistance and pure red cell aplasia.
- The exact reason for antibody production remains unclear but is linked to rHuEPO treatment.
- Early detection and immunosuppressive therapy are crucial for managing this condition.